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Motivation: CRISPR/Cas9 is a promising strategy that improves the efficacy of homology recombination, opening a wide 
number of possibilites for genome editing. The use of this technology on the reparation of single nucleotide mutations is being 
under investigation to recover the phenotype of a number of diseases, as the Crigler-Najjar syndrome.  
Methods: The genomic target sequence of the Ugt1a1 mouse gene was cloned into vectors that were designed to assess 
efficiency in the generation of double strand brakes (DSB) by engineered nucleases. We have designed different sgRNAs 
targeting this genomic region. The vectors were transfected into Hek293 together with a plasmid expressing the Cas9 
nucelase and the sgRNA, generating a DSB in the target sequence. After recombination, the inactive luciferase gene recovers 
activity, which is proportional to the cutting efficiency of the nuclease. Then, luciferase and T7 assays were used to determine 
the activity of gRNAs to target the specific genome locus.  
Results: Depending on the DNA sequence where is located the gRNA and, specially, the PAM sequences, we have obtained 
different results on the activity of our gRNAs. However, different factors, as the type of cells transfected or the vectors used, 
can affect the final activity of the gRNAs and thus, the whole CRISPR/Cas9 activity. 
Conclusions: With this project, it has been demonstrated the importance of a good design and optimization of the protocols to 
choose the most efficient gRNAs for CRISPR/Cas9 machinery, as well as in the vectors used to synthetize all the components 
needed.  
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